Product Categories
Featured products
Products/Services(52items)
news list
-
![Marrakech Patent Claim Drafting Tool [On-Demand Webinar]](https://image.mono.ipros.com/public/news/image/1/0f9/127202/IPROS13455807943524281802.png?w=280&h=280)
Marrakech Patent Claim Drafting Tool [On-Demand Webinar]
In the webinar, we will introduce how Markush Editor revolutionizes the creation of patent claims through a video lasting approximately 35 minutes. Markush claims are typically complex and labor-intensive, but by using Markush Editor, digital transformation (DX) becomes possible, reducing a task that previously took two weeks to just two days. Please join this webinar to see the effects for yourself. 【Overview】 - Introduction to Markush Editor - Presentation of specific operational images through a demo - Automatic creation of Markush structures from example structure groups - Inclusion check of example structures against Markush structures - Adjustment of Markush structures - Automatic generation of Markush claim drafts 【How to Watch】 Click on "MarkushEditor On-Demand Webinar" under "Related Links" below, download the PDF, and click the link button in the PDF to watch the webinar.
-

Excelra announces partnership with Patcoar.
Excelra has announced a partnership with Patcore to provide Japanese customers access to Excelra's scientific data and analytics products. Excelra is one of the world's leading companies in data and digital insights. Its GOSTAR platform is the largest manually curated medicinal chemistry information database, offering comprehensive and structured SAR (structure-activity relationship) data on over 9 million compounds. Excelra's GOBIOM includes the most extensive manually curated collection of verified and estimated biomarkers, providing critical insights into the relationship between biomarkers (biological indicator compounds) and diseases. Patcore is a highly specialized informatics company that supports researchers in the life sciences and chemical industries. This partnership leverages Patcore's strengths, which include experience working with some of Japan's largest pharmaceutical companies, biotechnology firms, chemical companies, and government agencies, to support Excelra's growth in Japan. For more details, please visit our website at the link below.
-
Chemical.AI and Chemaxon announce collaboration in the integration of scientific information software.
Chemical.AI, a global leader in artificial intelligence (AI) for synthetic route design and prediction, and Chemaxon, a leading company in chemical and biological software development, have announced a strategic partnership that will allow access to Chemical.AI's reverse synthesis tool, ChemAIRS, as an option from Chemaxon's drug discovery platform, Design Hub. This collaboration creates compatibility between Chemical.AI's ChemAIRS and Chemaxon's Design Hub, enabling a seamless user workflow and one-stop service that integrates compound design tracking and prioritization features from Design Hub with the innovative synthetic routes generated in minutes using ChemAIRS's diverse strategies. For more details, please visit our website.
-

Chemaxon announces the appointment of its new CEO, Richard Jonas.
Chemaxon, a leader in the development of cheminformatics software for life sciences research, has announced the appointment of Richard Jones as Chief Executive Officer (CEO). Richard succeeds the owner, Ferenc (Csizi) Csizmadia, in this role. Csizi will continue to serve as a founder while focusing on the establishment of Ancestralize, which is centered on health and well-being in the digital age. Additionally, coinciding with Mr. Richard's appointment, Chemaxon's Budapest office has relocated to the newly constructed environmentally friendly office park, Váci Greens, on the east side of the Danube River. A new logo and spelling have also been announced. For more details, please visit the news article on our company's homepage via the link below.
-

ChemAxon's response to the "Log4Shell" vulnerability.
▶ChemAxon's Response to CVE-2021-44228 ("Log4Shell") and CVE-2021-45046 Initial Release: December 15, 2021 Update: January 3, 2022 This vulnerability was disclosed by the Apache Log4j project on December 9, 2021 (Thursday). If exploited, it could allow remote attackers to execute code on the server if the system logs a string value controlled by the attacker to the affected endpoint. Immediately upon recognizing this vulnerability, ChemAxon evaluated all cloud hosting systems and on-premises software for customers, identified those that could be affected, and systematically began to address any exposures. All affected ChemAxon products have been updated to use log4j2.16, so no new incidents pose additional threats. For more details, please visit the Patcore or ChemAxon website.
Company Blog
-
Targeted Protein Degradation を段階的に解説:その科学とインパクトを理解する
はじめに タンパク質分解は細胞内において重要なプロセスです。これは細胞を健康に保ち、適切に機能させる役割を果たします。Targeted protein degradation(TPD)は、このプ...
-
Excelra、AsedaSciences® 戦略的共同マーケティング契約発表
Excelra と AsedaSciences® は、研究者が小分子毒性評価を行う際に利用できる、単一かつ使いやすいプラットフォームを提供するための戦略的共同マーケティング契約を締結したことを発...
-
GOSTARᵀᴹ TPD における Scaffold Landscape Analysis のご紹介
Targeted Protein Degrader の創薬が加速する中、有用なインサイトは単一化合物からではなく、化学シリーズに繰り返し現れるパターン、すなわち分子設計と生物活性をつなぐ共通スキ...
-
より高度な創薬設計と戦略的判断に向けて、GOSTARᵀᴹ TPD を 1 万件以上の新規デグレーダーで拡充
2025 年 4 月から 7 月にかけて、GOSTARᵀᴹ TPD データベースはコンテンツを 20% 追加しました。 1 万件を超える新規デグレーダー構造と、7 万件の構造活性相関(SAR)が...
-
科学的ソフトウェア設計:科学的思考を応用した事例研究
化学者であるあなたは、科学的手法を指針として生きています。あなたの世界は、仮説、反復的な最適化、そして厳密なデータ駆動型の検証で成り立っています。確かな証拠なしにリード化合物を進めることはなく、...
Aboutパトコア
PatCore for drug discovery, chemical substance management, and chemical patent DX support!
Patocoa Inc. is a specialized company in drug discovery support systems. Additionally, we focus on improving and streamlining compliance-related operations concerning regulated substances, and we have provided various solutions to pharmaceutical companies, chemical companies, universities, and government agencies. We contribute to accelerating drug discovery and reducing costs with our cutting-edge chemoinformatics systems.





